These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 36449257)

  • 41. Renal anaemia: recent developments, innovative approaches and future directions for improved management.
    Kerr PG
    Nephrology (Carlton); 2006 Dec; 11(6):542-8. PubMed ID: 17199795
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Impact of anemia correction on the production of the circulating morphogenetic protein α-Klotho in patients with Stages 3B-4 chronic kidney disease: A new direction of cardionephroprotection].
    Milovanov YS; Mukhin NA; Kozlovskaya LV; Milovanova SY; Markina MM
    Ter Arkh; 2016; 88(6):21-25. PubMed ID: 27296257
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Roxadustat in the treatment of anaemia in chronic kidney disease.
    Del Vecchio L; Locatelli F
    Expert Opin Investig Drugs; 2018 Jan; 27(1):125-133. PubMed ID: 29254377
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Use of intravenous iron supplementation in chronic kidney disease: Interests, limits, and recommendations for a better practice].
    Rottembourg J; Rostoker G
    Nephrol Ther; 2015 Dec; 11(7):531-42. PubMed ID: 26498106
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Patient Preferences for Attributes of Type 2 Diabetes Mellitus Medications in Germany and Spain: An Online Discrete-Choice Experiment Survey.
    Mansfield C; Sikirica MV; Pugh A; Poulos CM; Unmuessig V; Morano R; Martin AA
    Diabetes Ther; 2017 Dec; 8(6):1365-1378. PubMed ID: 29101681
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Patient preferences for atopic dermatitis medications in the UK, France and Spain: a discrete choice experiment.
    Thomas C; Raibouaa A; Wollenberg A; Capron JP; Krucien N; Karn H; Tervonen T
    BMJ Open; 2022 Aug; 12(8):e058799. PubMed ID: 35918108
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Anaemia management in patients with chronic kidney disease: Taiwan practice guidelines.
    Hung SC; Kuo KL; Tarng DC; Hsu CC; Wu MS; Huang TP
    Nephrology (Carlton); 2014 Dec; 19(12):735-9. PubMed ID: 25156587
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A Study of Patient Preferences for the Treatment of Non-small Cell Lung Cancer in Western China: A Discrete-Choice Experiment.
    Liu F; Hu H; Wang J; Chen Y; Hui S; Hu M
    Front Public Health; 2021; 9():653450. PubMed ID: 33842426
    [No Abstract]   [Full Text] [Related]  

  • 49. Molidustat for the treatment of renal anaemia in patients with non-dialysis-dependent chronic kidney disease: design and rationale of two phase III studies.
    Yamamoto H; Taguchi M; Matsuda Y; Iekushi K; Yamada T; Akizawa T
    BMJ Open; 2019 Jun; 9(6):e026704. PubMed ID: 31203242
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Preferences for medication attributes among patients with type 2 diabetes mellitus in the UK.
    Gelhorn HL; Stringer SM; Brooks A; Thompson C; Monz BU; Boye KS; Hach T; Lund SS; Palencia R
    Diabetes Obes Metab; 2013 Sep; 15(9):802-9. PubMed ID: 23464623
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis.
    Palmer SC; Saglimbene V; Mavridis D; Salanti G; Craig JC; Tonelli M; Wiebe N; Strippoli GF
    Cochrane Database Syst Rev; 2014 Dec; 2014(12):CD010590. PubMed ID: 25486075
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Targeting the hepcidin-ferroportin pathway in anaemia of chronic kidney disease.
    Sheetz M; Barrington P; Callies S; Berg PH; McColm J; Marbury T; Decker B; Dyas GL; Truhlar SME; Benschop R; Leung D; Berg J; Witcher DR
    Br J Clin Pharmacol; 2019 May; 85(5):935-948. PubMed ID: 30677788
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Relative Importance of Mode of Administration in Treatment Preferences among Plaque Psoriasis Patients in the United States.
    Feldman SR; Holmen Moeller A; Erntoft Idemyr ST; González JM
    J Health Econ Outcomes Res; 2017; 4(2):141-157. PubMed ID: 37661952
    [No Abstract]   [Full Text] [Related]  

  • 54. Importance of attributes and willingness to pay for oral anticoagulant therapy in patients with atrial fibrillation in China: A discrete choice experiment.
    Zhao J; Wang H; Li X; Hu Y; Yan VKC; Wong CKH; Guo Y; Cheung MKH; Lip GYH; Siu CW; Tse HF; Chan EW
    PLoS Med; 2021 Aug; 18(8):e1003730. PubMed ID: 34437553
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Renal prognoses by different target hemoglobin levels achieved by epoetin beta pegol dosing to chronic kidney disease patients with hyporesponsive anemia to erythropoiesis-stimulating agent: a multicenter open-label randomized controlled study.
    Tsuruya K; Hayashi T; Yamamoto H; Hase H; Nishi S; Yamagata K; Nangaku M; Wada T; Uemura Y; Ohashi Y; Hirakata H;
    Clin Exp Nephrol; 2021 May; 25(5):456-466. PubMed ID: 33411115
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Relationship between anaemia management at haemodialysis initiation and patient prognosis.
    Kataoka H; Tsuchiya K; Naganuma T; Okazaki M; Komatsu M; Kimura T; Shiohira S; Kawaguchi H; Nitta K
    Nephrology (Carlton); 2015 Dec; 20 Suppl 4():14-21. PubMed ID: 26456159
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Efficacy and safety of CKD-11101 (darbepoetin-alfa proposed biosimilar) compared with NESP in anaemic chronic kidney disease patients not on dialysis.
    Lee JH; Ha Chung B; Joo KW; Shin SK; Kim YL; Na KY; Do JY; Park SK; Shin BC; Lee JS; Kim YW; Kim SW; Lee KW; Kang GW; An WS; Shin GT; Han S; Yang CW
    Curr Med Res Opin; 2019 Jun; 35(6):1111-1118. PubMed ID: 30569763
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Roxadustat for the treatment of anaemia in chronic kidney disease patients not on dialysis: a Phase 3, randomized, open-label, active-controlled study (DOLOMITES).
    Barratt J; Andric B; Tataradze A; Schömig M; Reusch M; Valluri U; Mariat C
    Nephrol Dial Transplant; 2021 Aug; 36(9):1616-1628. PubMed ID: 34077510
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Are gastroenterologists less tolerant of treatment risks than patients? Benefit-risk preferences in Crohn's disease management.
    Johnson FR; Hauber B; Özdemir S; Siegel CA; Hass S; Sands BE
    J Manag Care Pharm; 2010 Oct; 16(8):616-28. PubMed ID: 20866166
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Anaemia in diabetic renal failure: is there a role for early erythropoietin treatment in preventing cardiovascular mortality?
    Abaterusso C; Pertica N; Lupo A; Ortalda V; Gambaro G
    Diabetes Obes Metab; 2008 Sep; 10(10):843-9. PubMed ID: 18093210
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.